U.S. label recordBone
Corrected · version 3 · September 15, 2026Abaloparatide
Related names: Tymlos
A parathyroid hormone-related peptide analogue. This profile cites a U.S. label record.
Browse profiles
Peptide directory
41 profiles spanning label, trial, enforcement, identity, and safety-review evidence. Coverage does not imply endorsement or completeness.
Showing 41 profiles
U.S. label recordDermatology
Afamelanotide
Related names: Scenesse
A melanocortin analogue. This profile cites a U.S. label record.
InvestigationalMetabolic
Amycretin
An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
UnapprovedUnapproved and safety records
BPC-157
Related names: Body protection compound 157
A research peptide represented by FDA compounding-review material and one selected trial-registry record.
U.S. label recordReproductive health
Bremelanotide
Related names: Vyleesi · PT-141
A melanocortin receptor agonist peptide. This profile cites a U.S. label record.
InvestigationalMetabolic
Cagrilintide
Related names: AM833
A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.
UnapprovedUnapproved and safety records
Corrected · version 2 · September 15, 2026CJC-1295
Related names: CJC-1295 DAC
FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.
U.S. label recordMetabolic
Corrected · version 3 · September 15, 2026Dulaglutide
Related names: Trulicity
A GLP-1 receptor agonist. This profile cites a Trulicity label.
U.S. approval recordRare disease
Corrected · version 4 · September 15, 2026Elamipretide
Related names: SS-31 · MTP-131 · Forzinity
FDA granted Forzinity (elamipretide) accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
Safety review recordSafety records
Corrected · version 2 · September 15, 2026Emideltide
Related names: DSIP
A peptide also called DSIP in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
Safety review recordSafety records
Corrected · version 2 · September 15, 2026Epitalon
Related names: AEDG · Epithalon
A synthetic tetrapeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
U.S. label recordMetabolic
Exenatide
A GLP-1 receptor agonist. This profile cites a U.S. label record.
Safety review recordSafety records
GHK-Cu
Related names: Copper tripeptide-1 · GHK copper
A copper-binding peptide named in FDA's list of bulk substances under evaluation for non-injectable compounding.
U.S. label recordMetabolic
Corrected · version 3 · September 15, 2026Glucagon
Related names: Gvoke VialDx
A peptide hormone. The cited U.S. label distinguishes Gvoke for severe hypoglycemia from Gvoke VialDx for diagnostic use.
U.S. label recordMetabolic
Insulin glargine-aldy
Related names: Langlara
A long-acting insulin analogue. This profile cites a U.S. prescription label.
UnapprovedUnapproved and safety records
Corrected · version 2 · September 15, 2026Ipamorelin
Related names: Ipamorelin acetate
FDA's August 2024 assessment distinguishes ipamorelin free base and acetate and evaluates evidence for growth hormone deficiency and postoperative ileus.
Safety review recordSafety records
Corrected · version 2 · September 15, 2026KPV
Related names: Lys-Pro-Val
A tripeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
U.S. label recordEndocrine
Lanreotide
Related names: Lanreotide acetate
A somatostatin analogue. This profile cites a U.S. label record.
U.S. label recordEndocrine
Leuprolide
Related names: Leuprolide acetate
A GnRH agonist. This profile cites a U.S. label record.
U.S. label recordGastrointestinal
Linaclotide
Related names: Linzess
A guanylate cyclase-C agonist peptide. This profile cites a U.S. label record.
U.S. label recordMetabolic
Liraglutide
Related names: Saxenda
A GLP-1 receptor agonist. This profile cites a U.S. label record.
U.S. label recordMetabolic
Corrected · version 3 · September 15, 2026Lixisenatide
Related names: Soliqua 100/33
A GLP-1 receptor agonist component. This profile cites a U.S. combination-product label.
InvestigationalMetabolic
Maridebart cafraglutide
Related names: MariTide · AMG 133
An antibody-peptide conjugate candidate. This profile cites a completed ClinicalTrials.gov study record.
Reported approvalMetabolic
Corrected · version 3 · September 15, 2026Mazdutide
Related names: IBI362 · LY3305677
A June 2025 Suzhou Industrial Park regulator report describes Chinese approval of mazdutide injection for long-term weight management in adults with obesity or overweight. A December 2025 Suzhou government report describes approved diabetes and weight-management indications in China.
Safety review recordSafety records
Corrected · version 3 · September 15, 2026MOTS-c
Related names: MOTS-C
A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.
U.S. label recordEndocrine
Octreotide
Related names: Octreotide acetate
A somatostatin analogue. This profile cites a U.S. label record.
InvestigationalMetabolic
Pemvidutide
Related names: ALT-801
A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
InvestigationalMetabolic
Petrelintide
Related names: ZP8396
An amylin analogue candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.
U.S. label recordGastrointestinal
Plecanatide
Related names: Trulance
A guanylate cyclase-C agonist peptide. This profile cites a U.S. label record.
U.S. label recordMetabolic
Pramlintide
Related names: SymlinPen
An amylin analogue. This profile cites a U.S. label record.
InvestigationalMetabolic
Retatrutide
Related names: LY3437943
A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
U.S. label recordMetabolic
Semaglutide
Related names: Wegovy · Ozempic · Rybelsus
A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.
Safety review recordSafety records
Corrected · version 2 · September 15, 2026Semax
A synthetic peptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
U.S. label recordRare disease
Setmelanotide
Related names: Imcivree
A melanocortin-4 receptor agonist. This profile cites a U.S. label record.
InvestigationalMetabolic
Survodutide
Related names: BI 456906
A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
Safety review recordSafety records
Corrected · version 3 · September 15, 2026TB-500
Related names: N-terminal acetylated 17-23 fragment of thymosin beta-4
A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.
U.S. label recordBone
Teriparatide
A parathyroid hormone analogue. This profile cites a U.S. label record.
U.S. label recordEndocrine
Corrected · version 3 · September 15, 2026Tesamorelin
Related names: Egrifta
A growth-hormone-releasing factor analogue. This profile cites a U.S. label record.
U.S. label recordMetabolic
Corrected · version 4 · September 15, 2026Tirzepatide
Related names: Zepbound · Mounjaro
A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.
U.S. label recordRare disease
Vosoritide
Related names: Voxzogo
A C-type natriuretic peptide analogue. This profile cites a U.S. label record.
U.S. label recordNeurology
Ziconotide
Related names: Prialt
A synthetic peptide. This profile cites a U.S. intrathecal-drug label.
No matching profile in the current collection.
Coverage is selective. Try another name or review what PeptideScanner currently covers.